ACE Convergence Acquisition Corp. (ACEVU)
Price:
9.77 USD
( - -0.01 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)

(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
Churchill Capital Corp X
VALUE SCORE:
7
2nd position
Range Capital Acquisition Corp.
VALUE SCORE:
10
The best
M3-Brigade Acquisition V Corp. Units
VALUE SCORE:
10
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
No data to display
No data to display
No data to display
No data to display
No data to display
No data to display
No data to display
DESCRIPTION
ACE Convergence Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses. It intends to focus on businesses in the IT infrastructure software and semiconductor sectors. ACE Convergence Acquisition Corp. was incorporated in 2020 and is based in Wilmington, Delaware.
NEWS

U.S. IPO Week Ahead: Tax Software Leads A Diverse 7-IPO Week
seekingalpha.com
2020-07-25 08:52:35Seven IPOs and one SPAC plan to raise $2.1 billion in the week ahead, led by tax software provider Vertex.

U.S. IPO Weekly Recap: Preclinical Biotech Nkarta Pops 166% In A 5 IPO Week
seekingalpha.com
2020-07-12 08:22:16Three biotechs, two Chinese issuers, and one SPAC went public this past week. Preclinical oncology biotech Nkarta popped 166% in the best first-day return for a $10+ million IPO since 2015.
No data to display

U.S. IPO Week Ahead: Tax Software Leads A Diverse 7-IPO Week
seekingalpha.com
2020-07-25 08:52:35Seven IPOs and one SPAC plan to raise $2.1 billion in the week ahead, led by tax software provider Vertex.

U.S. IPO Weekly Recap: Preclinical Biotech Nkarta Pops 166% In A 5 IPO Week
seekingalpha.com
2020-07-12 08:22:16Three biotechs, two Chinese issuers, and one SPAC went public this past week. Preclinical oncology biotech Nkarta popped 166% in the best first-day return for a $10+ million IPO since 2015.









